Get the Stockscreener App
66.81
1.20%
0.79
After Hours:
66.81
Edwards Lifesciences Corp stock is traded at $66.81, with a volume of 5.62M.
It is up +1.20% in the last 24 hours and up +7.74% over the past month.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US.
See More
Previous Close:
$66.02
Open:
$66.23
24h Volume:
5.62M
Relative Volume:
1.09
Market Cap:
$40.25B
Revenue:
$6.00B
Net Income/Loss:
$1.47B
P/E Ratio:
28.55
EPS:
2.34
Net Cash Flow:
$551.80M
1W Performance:
-4.50%
1M Performance:
+7.74%
6M Performance:
-24.36%
1Y Performance:
-13.19%
1-Day Range:
$65.47
$67.04
1-Week Range:
$64.70
$69.96
52-Week Range:
$58.93
$96.12
Edwards Lifesciences Corp Stock (EW) Company Profile
Name
Edwards Lifesciences Corp
Sector
Industry
Phone
(949) 250-2500
Address
ONE EDWARDS WAY, IRVINE, CA
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-11-23 | Downgrade | Citigroup | Buy → Neutral |
| Nov-28-23 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-26-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Neutral |
| Mar-08-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-31-23 | Downgrade | Bernstein | Outperform → Underperform |
| Jan-30-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-06-22 | Downgrade | Stifel | Buy → Hold |
| Oct-28-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-26-22 | Initiated | Mizuho | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-29-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-13-22 | Initiated | Truist | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Mar-16-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-27-22 | Reiterated | Citigroup | Buy |
| Jan-27-22 | Reiterated | Evercore ISI | Outperform |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | Stifel | Buy |
| Jan-27-22 | Reiterated | UBS | Neutral |
| Dec-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Dec-06-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-30-21 | Reiterated | Canaccord Genuity | Buy |
| Jul-30-21 | Reiterated | Deutsche Bank | Hold |
| Jul-30-21 | Reiterated | Jefferies | Buy |
| Jul-30-21 | Reiterated | Morgan Stanley | Overweight |
| Jul-30-21 | Reiterated | Oppenheimer | Outperform |
| Jul-30-21 | Reiterated | Stifel | Buy |
| Jul-30-21 | Reiterated | UBS | Neutral |
| Jul-30-21 | Reiterated | Wells Fargo | Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Apr-05-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-11-20 | Reiterated | Canaccord Genuity | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Underperform |
| Apr-28-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Outperform |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-24-19 | Reiterated | Canaccord Genuity | Buy |
| Sep-23-19 | Initiated | Piper Jaffray | Overweight |
| Jul-24-19 | Reiterated | BofA/Merrill | Buy |
| Mar-18-19 | Reiterated | Canaccord Genuity | Buy |
| Jan-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-19 | Initiated | Deutsche Bank | Hold |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-16-18 | Initiated | Barclays | Underweight |
| Oct-02-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Oct-02-18 | Downgrade | Guggenheim | Buy → Neutral |
View All
Edwards Lifesciences Corp Stock (EW) Latest News
We Think Edwards Lifesciences (NYSE:EW) Can Manage Its Debt With Ease - Yahoo Finance
Candriam S.C.A. Buys 150,662 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
National Bank of Canada FI Purchases 34,635 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
TD Asset Management Inc Sells 48,443 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Edwards’ Sapien TAVR devices superior to SAVR in women - BioWorld Online
Does Edwards Lifesciences (NYQ:EW) have an economic moat? - Yahoo Finance UK
Edwards Lifesciences Co. (NYSE:EW) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Edwards Lifesciences Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Edwards cuts more than 500 employees after critical care sale - Yahoo Finance
Edwards Lifesciences starts global layoffs - Mass Device
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
Edwards Lifesciences Completes $4.2B Sale of Critical Care to BD - Yahoo Finance
BD completes acquisition of Edwards Lifesciences’ Critical Care product group - Medical Device Network
Edwards Lifesciences Completes Sale of Critical Care - Quantisnow
BD acquires Edwards Lifesciences unit for smart care - Investing.com
Edwards Lifesciences Completes Sale of Critical Care - Yahoo Finance UK
BD Completes Acquisition of Critical Care from Edwards Lifesciences – Company Announcement - Financial Times
Spire Wealth Management Has $359,000 Holdings in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Van ECK Associates Corp - MarketBeat
Edwards Lifesciences reports positive TAVI trial results - Medical Device Network
Mirova US LLC Acquires 17,365 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future - Simply Wall St
5 of the Best Stocks to Buy Now | Investing - U.S News & World Report Money
Traders Buy High Volume of Put Options on Edwards Lifesciences (NYSE:EW) - MarketBeat
Investors in Edwards Lifesciences (NYSE:EW) have unfortunately lost 43% over the last three years - Yahoo Finance
Kintegral Advisory LLC Has $6.74 Million Holdings in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
The Broad Impact of Edwards v. Meril on the Safe Harbor Provision - The National Law Review
Calamos Advisors LLC Decreases Stock Position in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Intracardiac Oximeter Market Growing Rapidly by 2031- Edwards Lifesciences Corporation, Medtronic - openPR
Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Baillie Gifford & Co. - MarketBeat
Could The Market Be Wrong About Edwards Lifesciences Corporation (NYSE:EW) Given Its Attractive Financial Prospects? - Yahoo Finance
Edwards Lifesciences (EW) Up 19.4% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Fifth Third Bancorp - Defense World
Catheters Market Set to Reach USD 99.30 Billion by 2032, Growing at a CAGR of 7.2% | Polaris Market Research - GlobeNewswire Inc.
Edwards Lifesciences stock set for rebound amid TMTT optimismCiti - Investing.com
Chevy Chase Trust Holdings LLC Cuts Position in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Edwards Lifesciences executive sells over $87k in company stock By Investing.com - Investing.com Australia
Edwards Lifesciences to Present at the 2024 Wells Fargo Healthcare Conference - sharewise
Edwards Lifesciences Co. (NYSE:EW) VP Daveen Chopra Sells 1,250 Shares - Defense World
Edwards Lifesciences to Present at the 2024 Wells Fargo Healthcare Conference - Yahoo Finance
Edwards Lifesciences executive sells over $87k in company stock By Investing.com - Investing.com Canada
Edwards Lifesciences executive sells over $87k in company stock - Investing.com India
Insider Selling: Edwards Lifesciences Co. (NYSE:EW) VP Sells 1,250 Shares of Stock - MarketBeat
Edwards Lifesciences executive sells over $87k in company stock - Investing.com
Edwards Lifesciences executive sells over $87k in company stock By Investing.com - Investing.com UK
Edwards Lifesciences (NYSE:EW) Trading Up 2.3% - MarketBeat
Edwards Buys JC Medical from Genesis MedTech - Orange County Business Journal
Edwards Lifesciences acquires JC Medical from Genesis Medtech - Medical Device Network
Edwards Lifesciences acquires JC Medical from Genesis Medtech - Yahoo Finance
Edwards Lifesciences (BSP:E1WL34) PB Ratio : 1.42 (As of Aug. 19, 2024) - GuruFocus.com
Edwards Lifesciences maintains neutral rating with $73 target - Investing.com
Edwards Lifesciences Corp Stock (EW) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
1.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):